Recent advances and future of immunotherapy for glioblastoma

Autores
Kamran, Neha; Calinescu, Alexandra; Candolfi, Marianela; Chandran, Mayuri; Mineharu, Yohei; Asad, Antonela Sofía; Koschmann, Carl; Nunez, Felipe; Lowenstein, Pedro R.; Castro, Maria Gabriela
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: Outcome for glioma (GBM) remains dismal despite advances in therapeutic interventions including chemotherapy, radiotherapy and surgical resection. The overall survival benefit observed with immunotherapies in cancers such as melanoma and prostate cancer has fuelled research into evaluating immunotherapies for GBM. Areas covered: Preclinical studies have brought a wealth of information for improving the prognosis of GBM and multiple clinical studies are evaluating a wide array of immunotherapies for GBM patients. This review highlights advances in the development of immunotherapeutic approaches. We discuss the strategies and outcomes of active and passive immunotherapies for GBM including vaccination strategies, gene therapy, check point blockade and adoptive T cell therapies. We also focus on immunoediting and tumor neoantigens that can impact the efficacy of immunotherapies. Expert opinion: Encouraging results have been observed with immunotherapeutic strategies; some clinical trials are reaching phase III. Significant progress has been made in unraveling the molecular and genetic heterogeneity of GBM and its implications to disease prognosis. There is now consensus related to the critical need to incorporate tumor heterogeneity into the design of therapeutic approaches. Recent data also indicates that an efficacious treatment strategy will need to be combinatorial and personalized to the tumor genetic signature.
Fil: Kamran, Neha. University of Michigan; Estados Unidos
Fil: Calinescu, Alexandra. University of Michigan; Estados Unidos
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Chandran, Mayuri. University of Michigan; Estados Unidos
Fil: Mineharu, Yohei. Kyoto University; Japón
Fil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Koschmann, Carl. University of Michigan; Estados Unidos
Fil: Nunez, Felipe. University of Michigan; Estados Unidos
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
Fil: Castro, Maria Gabriela. University of Michigan; Estados Unidos
Materia
Cancer Vaccines
Checkpoint Blockade
Gene Therapy
Glioma
Immunotherapy
Passive Immunotherapy
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/51640
Acceder
id CONICETDig_d71a70c9b238880454eb6e543a5ded11
oai_identifier_str oai:ri.conicet.gov.ar:11336/51640
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Recent advances and future of immunotherapy for glioblastomaKamran, NehaCalinescu, AlexandraCandolfi, MarianelaChandran, MayuriMineharu, YoheiAsad, Antonela SofíaKoschmann, CarlNunez, FelipeLowenstein, Pedro R.Castro, Maria GabrielaCancer VaccinesCheckpoint BlockadeGene TherapyGliomaImmunotherapyPassive Immunotherapyhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Introduction: Outcome for glioma (GBM) remains dismal despite advances in therapeutic interventions including chemotherapy, radiotherapy and surgical resection. The overall survival benefit observed with immunotherapies in cancers such as melanoma and prostate cancer has fuelled research into evaluating immunotherapies for GBM. Areas covered: Preclinical studies have brought a wealth of information for improving the prognosis of GBM and multiple clinical studies are evaluating a wide array of immunotherapies for GBM patients. This review highlights advances in the development of immunotherapeutic approaches. We discuss the strategies and outcomes of active and passive immunotherapies for GBM including vaccination strategies, gene therapy, check point blockade and adoptive T cell therapies. We also focus on immunoediting and tumor neoantigens that can impact the efficacy of immunotherapies. Expert opinion: Encouraging results have been observed with immunotherapeutic strategies; some clinical trials are reaching phase III. Significant progress has been made in unraveling the molecular and genetic heterogeneity of GBM and its implications to disease prognosis. There is now consensus related to the critical need to incorporate tumor heterogeneity into the design of therapeutic approaches. Recent data also indicates that an efficacious treatment strategy will need to be combinatorial and personalized to the tumor genetic signature.Fil: Kamran, Neha. University of Michigan; Estados UnidosFil: Calinescu, Alexandra. University of Michigan; Estados UnidosFil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Chandran, Mayuri. University of Michigan; Estados UnidosFil: Mineharu, Yohei. Kyoto University; JapónFil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Koschmann, Carl. University of Michigan; Estados UnidosFil: Nunez, Felipe. University of Michigan; Estados UnidosFil: Lowenstein, Pedro R.. University of Michigan; Estados UnidosFil: Castro, Maria Gabriela. University of Michigan; Estados UnidosInforma Healthcare2016-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/51640Kamran, Neha; Calinescu, Alexandra; Candolfi, Marianela; Chandran, Mayuri; Mineharu, Yohei; et al.; Recent advances and future of immunotherapy for glioblastoma; Informa Healthcare; Expert Opinion on Biological Therapy; 16; 10; 10-2016; 1245-12641471-2598CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14712598.2016.1212012info:eu-repo/semantics/altIdentifier/doi/10.1080/14712598.2016.1212012info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014608/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:29:48Zoai:ri.conicet.gov.ar:11336/51640instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:29:48.912CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Recent advances and future of immunotherapy for glioblastoma
title Recent advances and future of immunotherapy for glioblastoma
spellingShingle Recent advances and future of immunotherapy for glioblastoma
Kamran, Neha
Cancer Vaccines
Checkpoint Blockade
Gene Therapy
Glioma
Immunotherapy
Passive Immunotherapy
title_short Recent advances and future of immunotherapy for glioblastoma
title_full Recent advances and future of immunotherapy for glioblastoma
title_fullStr Recent advances and future of immunotherapy for glioblastoma
title_full_unstemmed Recent advances and future of immunotherapy for glioblastoma
title_sort Recent advances and future of immunotherapy for glioblastoma
dc.creator.none.fl_str_mv Kamran, Neha
Calinescu, Alexandra
Candolfi, Marianela
Chandran, Mayuri
Mineharu, Yohei
Asad, Antonela Sofía
Koschmann, Carl
Nunez, Felipe
Lowenstein, Pedro R.
Castro, Maria Gabriela
author Kamran, Neha
author_facet Kamran, Neha
Calinescu, Alexandra
Candolfi, Marianela
Chandran, Mayuri
Mineharu, Yohei
Asad, Antonela Sofía
Koschmann, Carl
Nunez, Felipe
Lowenstein, Pedro R.
Castro, Maria Gabriela
author_role author
author2 Calinescu, Alexandra
Candolfi, Marianela
Chandran, Mayuri
Mineharu, Yohei
Asad, Antonela Sofía
Koschmann, Carl
Nunez, Felipe
Lowenstein, Pedro R.
Castro, Maria Gabriela
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cancer Vaccines
Checkpoint Blockade
Gene Therapy
Glioma
Immunotherapy
Passive Immunotherapy
topic Cancer Vaccines
Checkpoint Blockade
Gene Therapy
Glioma
Immunotherapy
Passive Immunotherapy
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: Outcome for glioma (GBM) remains dismal despite advances in therapeutic interventions including chemotherapy, radiotherapy and surgical resection. The overall survival benefit observed with immunotherapies in cancers such as melanoma and prostate cancer has fuelled research into evaluating immunotherapies for GBM. Areas covered: Preclinical studies have brought a wealth of information for improving the prognosis of GBM and multiple clinical studies are evaluating a wide array of immunotherapies for GBM patients. This review highlights advances in the development of immunotherapeutic approaches. We discuss the strategies and outcomes of active and passive immunotherapies for GBM including vaccination strategies, gene therapy, check point blockade and adoptive T cell therapies. We also focus on immunoediting and tumor neoantigens that can impact the efficacy of immunotherapies. Expert opinion: Encouraging results have been observed with immunotherapeutic strategies; some clinical trials are reaching phase III. Significant progress has been made in unraveling the molecular and genetic heterogeneity of GBM and its implications to disease prognosis. There is now consensus related to the critical need to incorporate tumor heterogeneity into the design of therapeutic approaches. Recent data also indicates that an efficacious treatment strategy will need to be combinatorial and personalized to the tumor genetic signature.
Fil: Kamran, Neha. University of Michigan; Estados Unidos
Fil: Calinescu, Alexandra. University of Michigan; Estados Unidos
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Chandran, Mayuri. University of Michigan; Estados Unidos
Fil: Mineharu, Yohei. Kyoto University; Japón
Fil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Koschmann, Carl. University of Michigan; Estados Unidos
Fil: Nunez, Felipe. University of Michigan; Estados Unidos
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
Fil: Castro, Maria Gabriela. University of Michigan; Estados Unidos
description Introduction: Outcome for glioma (GBM) remains dismal despite advances in therapeutic interventions including chemotherapy, radiotherapy and surgical resection. The overall survival benefit observed with immunotherapies in cancers such as melanoma and prostate cancer has fuelled research into evaluating immunotherapies for GBM. Areas covered: Preclinical studies have brought a wealth of information for improving the prognosis of GBM and multiple clinical studies are evaluating a wide array of immunotherapies for GBM patients. This review highlights advances in the development of immunotherapeutic approaches. We discuss the strategies and outcomes of active and passive immunotherapies for GBM including vaccination strategies, gene therapy, check point blockade and adoptive T cell therapies. We also focus on immunoediting and tumor neoantigens that can impact the efficacy of immunotherapies. Expert opinion: Encouraging results have been observed with immunotherapeutic strategies; some clinical trials are reaching phase III. Significant progress has been made in unraveling the molecular and genetic heterogeneity of GBM and its implications to disease prognosis. There is now consensus related to the critical need to incorporate tumor heterogeneity into the design of therapeutic approaches. Recent data also indicates that an efficacious treatment strategy will need to be combinatorial and personalized to the tumor genetic signature.
publishDate 2016
dc.date.none.fl_str_mv 2016-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/51640
Kamran, Neha; Calinescu, Alexandra; Candolfi, Marianela; Chandran, Mayuri; Mineharu, Yohei; et al.; Recent advances and future of immunotherapy for glioblastoma; Informa Healthcare; Expert Opinion on Biological Therapy; 16; 10; 10-2016; 1245-1264
1471-2598
CONICET Digital
CONICET
url http://hdl.handle.net/11336/51640
identifier_str_mv Kamran, Neha; Calinescu, Alexandra; Candolfi, Marianela; Chandran, Mayuri; Mineharu, Yohei; et al.; Recent advances and future of immunotherapy for glioblastoma; Informa Healthcare; Expert Opinion on Biological Therapy; 16; 10; 10-2016; 1245-1264
1471-2598
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14712598.2016.1212012
info:eu-repo/semantics/altIdentifier/doi/10.1080/14712598.2016.1212012
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014608/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Informa Healthcare
publisher.none.fl_str_mv Informa Healthcare
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614305609154560
score 13.069144

Publicaciones similares